Wei Leong Chew
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wei Leong Chew has a total of 155 co-authors. Here are the top co-authors by number of shared publications:
Choong Tat Keng
Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), 60 Biopolis Street, Genome, Singapore, Republic of Singapore
5 shared publicationsKe Guo
Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), 60 Biopolis Street, Genome, Singapore, Republic of Singapore
5 shared publicationsKimberle Shen
Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), 60 Biopolis Street, Genome, Singapore, Republic of Singapore
4 shared publications- George McDonald Church
Department of Genetics, Harvard Medical School, Boston, MA, USA
3 shared publications - Prashant Mali
Department of Bioengineering, University of California San Diego, La Jolla, CA, USA
3 shared publications Amine Meliani
Genome Institute of Singapore (GIS), Agency for Science, Technology and Research (A*STAR), 60 Biopolis Street, Genome, Singapore, Republic of Singapore
2 shared publications
Latest Publications
- Top Cited PapersOpen Access
- 21 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Spatial perturb-seq: single-cell functional genomics within intact tissue architecture
We develop Spatial Perturb-Seq, an in vivo CRISPR technology that interrogates multiple genes within single cells of intact tissues, compatible with both sequencing-based and probe-based spatial technologies. We apply Spatial Perturb-Seq to knock out risk genes for neurodegenerative diseases in the mouse brain, uncovering cell autonomous and cell-cell microenvironmental effects within the spatially intact tissue. Spatial Perturb-Seq functionally screens multiple genes in situ and in vivo, bypasses cell processing steps that skew cell type representation, identifies intracellular and intercellular effects of knockouts, and identifies candidate genes underlying dysregulated neuronal intercellular communication pathways.
- 21 February 2026
- Published by Springer Nature in Nature Communications
- Vol. 17 (1)
Top Cited PapersOpen AccessSpatial perturb-seq: single-cell functional genomics within intact tissue architecture
We develop Spatial Perturb-Seq, an in vivo CRISPR technology that interrogates multiple genes within single cells of intact tissues, compatible with both sequencing-based and probe-based spatial technologies. We apply Spatial Perturb-Seq to knock out risk genes for neurodegenerative diseases in the mouse brain, uncovering cell autonomous and cell-cell microenvironmental effects within the spatially intact tissue. Spatial Perturb-Seq functionally screens multiple genes in situ and in vivo, bypasses cell processing steps that skew cell type representation, identifies intracellular and intercellular effects of knockouts, and identifies candidate genes underlying dysregulated neuronal intercellular communication pathways.
- 30 June 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (27) , 24724-24735
Polyethylene-Glycol-Conjugated Peptide Coacervates with Tunable Size for Intracellular mRNA Delivery
Coacervate microdroplets (CMs), formed through liquid-liquid phase separation (LLPS) of biomacromolecules, hold significant potential for biomedical applications such as intracellular delivery vehicles or enhanced microcatalytic reactors. However, their micrometer size and tendency to coalesce are sometimes deemed unsuitable for those applications. Here, we introduce a strategy to control the size and stability of peptide-based coacervates derived from histidine-rich beak peptides (HBpep) by conjugating the peptides with poly(ethylene glycol) (PEG) and preparing mixtures of PEGylated and non-PEGylated HBpep. PEGylation introduces steric hindrance, stabilizing the coacervates in the nanoscale size range with controlled size distribution depending on the PEGylated-to-non-PEGylated peptide ratio, but initially affects cellular uptake and cargo recruitment of the resultant coacervate nanodroplets (CNs). By incorporating positively charged residues into the peptide sequence, mRNA recruitment and intracellular delivery abilities of CNs are restored. Furthermore, PEG-stabilized CNs exhibit improved cellular uptake and mRNA transfection at the physiological temperature of 37 °C. This approach expands the molecular design of LLPS-based delivery systems with potential for targeted in vivo applications and also highlights opportunities for adapting coacervate-based technologies in catalysis and bioreactors.
- 30 June 2025
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 19 (27) , 24724-24735
Polyethylene-Glycol-Conjugated Peptide Coacervates with Tunable Size for Intracellular mRNA Delivery
Coacervate microdroplets (CMs), formed through liquid-liquid phase separation (LLPS) of biomacromolecules, hold significant potential for biomedical applications such as intracellular delivery vehicles or enhanced microcatalytic reactors. However, their micrometer size and tendency to coalesce are sometimes deemed unsuitable for those applications. Here, we introduce a strategy to control the size and stability of peptide-based coacervates derived from histidine-rich beak peptides (HBpep) by conjugating the peptides with poly(ethylene glycol) (PEG) and preparing mixtures of PEGylated and non-PEGylated HBpep. PEGylation introduces steric hindrance, stabilizing the coacervates in the nanoscale size range with controlled size distribution depending on the PEGylated-to-non-PEGylated peptide ratio, but initially affects cellular uptake and cargo recruitment of the resultant coacervate nanodroplets (CNs). By incorporating positively charged residues into the peptide sequence, mRNA recruitment and intracellular delivery abilities of CNs are restored. Furthermore, PEG-stabilized CNs exhibit improved cellular uptake and mRNA transfection at the physiological temperature of 37 °C. This approach expands the molecular design of LLPS-based delivery systems with potential for targeted in vivo applications and also highlights opportunities for adapting coacervate-based technologies in catalysis and bioreactors.
- Open Access
- 25 February 2025
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 14 (3) , 636-647
Engineering a New Generation of Gene Editors: Integrating Synthetic Biology and AI Innovations
CRISPR-Cas technology has revolutionized biology by enabling precise DNA and RNA edits with ease. However, significant challenges remain for translating this technology into clinical applications. Traditional protein engineering methods, such as rational design, mutagenesis screens, and directed evolution, have been used to address issues like low efficacy, specificity, and high immunogenicity. These methods are labor-intensive, time-consuming, and resource-intensive and often require detailed structural knowledge. Recently, computational strategies have emerged as powerful solutions to these limitations. Using artificial intelligence (AI) and machine learning (ML), the discovery and design of novel gene-editing enzymes can be streamlined. AI/ML models predict activity, specificity, and immunogenicity while also enhancing mutagenesis screens and directed evolution. These approaches not only accelerate rational design but also create new opportunities for developing safer and more efficient genome-editing tools, which could eventually be translated into the clinic.
- 25 February 2025
- Published by American Chemical Society (ACS) in ACS Synthetic Biology
- Vol. 14 (3) , 636-647
Open AccessEngineering a New Generation of Gene Editors: Integrating Synthetic Biology and AI Innovations
CRISPR-Cas technology has revolutionized biology by enabling precise DNA and RNA edits with ease. However, significant challenges remain for translating this technology into clinical applications. Traditional protein engineering methods, such as rational design, mutagenesis screens, and directed evolution, have been used to address issues like low efficacy, specificity, and high immunogenicity. These methods are labor-intensive, time-consuming, and resource-intensive and often require detailed structural knowledge. Recently, computational strategies have emerged as powerful solutions to these limitations. Using artificial intelligence (AI) and machine learning (ML), the discovery and design of novel gene-editing enzymes can be streamlined. AI/ML models predict activity, specificity, and immunogenicity while also enhancing mutagenesis screens and directed evolution. These approaches not only accelerate rational design but also create new opportunities for developing safer and more efficient genome-editing tools, which could eventually be translated into the clinic.
- Open Access
Spatial Perturb-Seq: Single-Cell Functional Genomics within Intact Tissue Architecture
We develop Spatial Perturb-Seq, an in vivo CRISPR technology that interrogates multiple genes within single cells of intact tissues. We apply Spatial Perturb-Seq to screen risk genes for neurodegenerative diseases in the mouse brain, uncovering cell autonomous and cell-cell microenvironmental effects within the spatially intact tissue. Spatial Perturb-Seq functionally screens multiple genes in situ and in vivo , identifying candidate genes underlying dysregulated neuronal intercellular communication pathways in Lrp1 signalling and ephrin-Eph receptor interactions.
Open AccessSpatial Perturb-Seq: Single-Cell Functional Genomics within Intact Tissue Architecture
We develop Spatial Perturb-Seq, an in vivo CRISPR technology that interrogates multiple genes within single cells of intact tissues. We apply Spatial Perturb-Seq to screen risk genes for neurodegenerative diseases in the mouse brain, uncovering cell autonomous and cell-cell microenvironmental effects within the spatially intact tissue. Spatial Perturb-Seq functionally screens multiple genes in situ and in vivo , identifying candidate genes underlying dysregulated neuronal intercellular communication pathways in Lrp1 signalling and ephrin-Eph receptor interactions.
- 6 November 2024
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 26 (5) , 298-319
The design and engineering of synthetic genomes
Synthetic genomics seeks to design and construct entire genomes to mechanistically dissect fundamental questions of genome function and to engineer organisms for diverse applications, including bioproduction of high-value chemicals and biologics, advanced cell therapies, and stress-tolerant crops. Recent progress has been fuelled by advancements in DNA synthesis, assembly, delivery and editing. Computational innovations, such as the use of artificial intelligence to provide prediction of function, also provide increasing capabilities to guide synthetic genome design and construction. However, translating synthetic genome-scale projects from idea to implementation remains highly complex. Here, we aim to streamline this implementation process by comprehensively reviewing the strategies for design, construction, delivery, debugging and tailoring of synthetic genomes as well as their potential applications.
- 6 November 2024
- Published by Springer Nature in Nature Reviews Genetics
- Vol. 26 (5) , 298-319
The design and engineering of synthetic genomes
Synthetic genomics seeks to design and construct entire genomes to mechanistically dissect fundamental questions of genome function and to engineer organisms for diverse applications, including bioproduction of high-value chemicals and biologics, advanced cell therapies, and stress-tolerant crops. Recent progress has been fuelled by advancements in DNA synthesis, assembly, delivery and editing. Computational innovations, such as the use of artificial intelligence to provide prediction of function, also provide increasing capabilities to guide synthetic genome design and construction. However, translating synthetic genome-scale projects from idea to implementation remains highly complex. Here, we aim to streamline this implementation process by comprehensively reviewing the strategies for design, construction, delivery, debugging and tailoring of synthetic genomes as well as their potential applications.
- Open Access
- 28 June 2023
- Published by Elsevier in EBioMedicine
- Vol. 93, 104682
AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice
- 28 June 2023
- Published by Elsevier in EBioMedicine
- Vol. 93, 104682
Open AccessAAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected mice
- Open Access
- 23 August 2022
- Published by Springer Nature in Gene Therapy
- Vol. 29 (9) , 555-565
Multiplex viral tropism assay in complex cell populations with single-cell resolution
Gene therapy constitutes one of the most promising mode of disease treatments. Two key properties for therapeutic delivery vectors are its transduction efficiency (how well the vector delivers therapeutic cargo to desired target cells) and specificity (how well it avoids off-target delivery into unintended cells within the body). Here we developed an integrated bioinformatics and experimental pipeline that enables multiplex measurement of transduction efficiency and specificity, particularly by measuring how libraries of delivery vectors transduce libraries of diverse cell types. We demonstrated that pairing high-throughput measurement of AAV identity with high-resolution single-cell RNA transcriptomic sequencing maps how natural and engineered AAV variants transduce individual cells within human cerebral and ocular organoids. We further demonstrate that efficient AAV transduction observed in organoids is recapitulated in vivo in non-human primates. This library-on-library technology will be important for determining the safety and efficacy of therapeutic delivery vectors.
- 23 August 2022
- Published by Springer Nature in Gene Therapy
- Vol. 29 (9) , 555-565
Open AccessMultiplex viral tropism assay in complex cell populations with single-cell resolution
Gene therapy constitutes one of the most promising mode of disease treatments. Two key properties for therapeutic delivery vectors are its transduction efficiency (how well the vector delivers therapeutic cargo to desired target cells) and specificity (how well it avoids off-target delivery into unintended cells within the body). Here we developed an integrated bioinformatics and experimental pipeline that enables multiplex measurement of transduction efficiency and specificity, particularly by measuring how libraries of delivery vectors transduce libraries of diverse cell types. We demonstrated that pairing high-throughput measurement of AAV identity with high-resolution single-cell RNA transcriptomic sequencing maps how natural and engineered AAV variants transduce individual cells within human cerebral and ocular organoids. We further demonstrate that efficient AAV transduction observed in organoids is recapitulated in vivo in non-human primates. This library-on-library technology will be important for determining the safety and efficacy of therapeutic delivery vectors.
- Open Access
- 5 August 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-16
Disrupting the LINC complex by AAV mediated gene transduction prevents progression of Lamin induced cardiomyopathy
Mutations in the LaminA gene are a common cause of monogenic dilated cardiomyopathy. Here we show that mice with a cardiomyocyte-specific Lmna deletion develop cardiac failure and die within 3–4 weeks after inducing the mutation. When the same Lmna mutations are induced in mice genetically deficient in the LINC complex protein SUN1, life is extended to more than one year. Disruption of SUN1’s function is also accomplished by transducing and expressing a dominant-negative SUN1 miniprotein in Lmna deficient cardiomyocytes, using the cardiotrophic Adeno Associated Viral Vector 9. The SUN1 miniprotein disrupts binding between the endogenous LINC complex SUN and KASH domains, displacing the cardiomyocyte KASH complexes from the nuclear periphery, resulting in at least a fivefold extension in lifespan. Cardiomyocyte-specific expression of the SUN1 miniprotein prevents cardiomyopathy progression, potentially avoiding the necessity of developing a specific therapeutic tailored to treating each different LMNA cardiomyopathy-inducing mutation of which there are more than 450.
- 5 August 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-16
Open AccessDisrupting the LINC complex by AAV mediated gene transduction prevents progression of Lamin induced cardiomyopathy
Mutations in the LaminA gene are a common cause of monogenic dilated cardiomyopathy. Here we show that mice with a cardiomyocyte-specific Lmna deletion develop cardiac failure and die within 3–4 weeks after inducing the mutation. When the same Lmna mutations are induced in mice genetically deficient in the LINC complex protein SUN1, life is extended to more than one year. Disruption of SUN1’s function is also accomplished by transducing and expressing a dominant-negative SUN1 miniprotein in Lmna deficient cardiomyocytes, using the cardiotrophic Adeno Associated Viral Vector 9. The SUN1 miniprotein disrupts binding between the endogenous LINC complex SUN and KASH domains, displacing the cardiomyocyte KASH complexes from the nuclear periphery, resulting in at least a fivefold extension in lifespan. Cardiomyocyte-specific expression of the SUN1 miniprotein prevents cardiomyopathy progression, potentially avoiding the necessity of developing a specific therapeutic tailored to treating each different LMNA cardiomyopathy-inducing mutation of which there are more than 450.
- Open Access
Multiplex viral tropism assay in complex cell populations with single-cell resolution
Gene therapy constitutes one of the most promising modes of disease treatments. Two key properties for therapeutic delivery vectors are the transduction efficiency (how well the vector delivers therapeutic cargo to desired target cells) and specificity (how well it avoids off-target delivery into the other unintended cells within the body). Here we developed a novel technology that enables multiplex measurement of transduction efficiency and specificity, particularly by measuring how libraries of delivery vectors transduce libraries of diverse cell types. We demonstrated that pairing high-throughput measurement of AAV identity with high-resolution single-cell RNA transcriptomic sequencing maps how natural and engineered AAV variants transduce individual cells within human cerebral and ocular organoids. This library- on-library technology is important for determining the safety and efficacy of therapeutic delivery vectors.
Open AccessMultiplex viral tropism assay in complex cell populations with single-cell resolution
Gene therapy constitutes one of the most promising modes of disease treatments. Two key properties for therapeutic delivery vectors are the transduction efficiency (how well the vector delivers therapeutic cargo to desired target cells) and specificity (how well it avoids off-target delivery into the other unintended cells within the body). Here we developed a novel technology that enables multiplex measurement of transduction efficiency and specificity, particularly by measuring how libraries of delivery vectors transduce libraries of diverse cell types. We demonstrated that pairing high-throughput measurement of AAV identity with high-resolution single-cell RNA transcriptomic sequencing maps how natural and engineered AAV variants transduce individual cells within human cerebral and ocular organoids. This library- on-library technology is important for determining the safety and efficacy of therapeutic delivery vectors.
- Open Access
- 9 April 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-22
Coding and non-coding roles of MOCCI (C15ORF48) coordinate to regulate host inflammation and immunity
Mito-SEPs are small open reading frame-encoded peptides that localize to the mitochondria to regulate metabolism. Motivated by an intriguing negative association between mito-SEPs and inflammation, here we screen for mito-SEPs that modify inflammatory outcomes and report a mito-SEP named “Modulator of cytochrome C oxidase during Inflammation” (MOCCI) that is upregulated during inflammation and infection to promote host-protective resolution. MOCCI, a paralog of the NDUFA4 subunit of cytochrome C oxidase (Complex IV), replaces NDUFA4 in Complex IV during inflammation to lower mitochondrial membrane potential and reduce ROS production, leading to cyto-protection and dampened immune response. The MOCCI transcript also generates miR-147b, which targets the NDUFA4 mRNA with similar immune dampening effects as MOCCI, but simultaneously enhances RIG-I/MDA-5-mediated viral immunity. Our work uncovers a dual-component pleiotropic regulation of host inflammation and immunity by MOCCI (C15ORF48) for safeguarding the host during infection and inflammation.
- 9 April 2021
- Published by Springer Nature in Nature Communications
- Vol. 12 (1) , 1-22
Open AccessCoding and non-coding roles of MOCCI (C15ORF48) coordinate to regulate host inflammation and immunity
Mito-SEPs are small open reading frame-encoded peptides that localize to the mitochondria to regulate metabolism. Motivated by an intriguing negative association between mito-SEPs and inflammation, here we screen for mito-SEPs that modify inflammatory outcomes and report a mito-SEP named “Modulator of cytochrome C oxidase during Inflammation” (MOCCI) that is upregulated during inflammation and infection to promote host-protective resolution. MOCCI, a paralog of the NDUFA4 subunit of cytochrome C oxidase (Complex IV), replaces NDUFA4 in Complex IV during inflammation to lower mitochondrial membrane potential and reduce ROS production, leading to cyto-protection and dampened immune response. The MOCCI transcript also generates miR-147b, which targets the NDUFA4 mRNA with similar immune dampening effects as MOCCI, but simultaneously enhances RIG-I/MDA-5-mediated viral immunity. Our work uncovers a dual-component pleiotropic regulation of host inflammation and immunity by MOCCI (C15ORF48) for safeguarding the host during infection and inflammation.